Kalaris Therapeutics (KLRS) Receivables - Accured (2019 - 2024)
Kalaris Therapeutics (KLRS) posted Receivables - Accured of $53,000 for Q3 2024, down 77.4% from $234,000 a year earlier and down 44.8% from the prior quarter.
Powered by 
Analysis
Kalaris Therapeutics (KLRS) Receivables - Accured (2019 - 2024) Analysis & Trends
At the end of FY2023, Kalaris Therapeutics' Receivables - Accured came in at $206,000, up 31.2% from FY2022.
- Annual Receivables - Accured shows a four-year compound annual growth rate of -5.8% (FY2019 to FY2023).
- In prior years, Kalaris Therapeutics' Receivables - Accured was $157,000 in FY2022 (+214.0%), $50,000 in FY2021 (-88.9%), $450,000 in FY2020 (+71.8%) and $262,000 in FY2019.
- The Q3 2024 figure stands as the lowest quarterly Receivables - Accured since Q4 2021.
- On a year-over-year basis, Receivables - Accured has declined in each of the last three quarters, with growth averaging 22.6% over the last eight quarters.
- The strongest year-over-year quarter for Receivables - Accured in the past five years was Q2 2021, with growth of 605.2%; the weakest was Q4 2021, with a decline of 88.9%.
- According to Business Quant data, Receivables - Accured for the three prior quarters was $96,000 (Q2 2024), $181,000 (Q1 2024) and $206,000 (Q4 2023).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables - Accured (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | - |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | - |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | - |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | - |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | - |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | - |
| 10 | Kalaris Therapeutics | 67.84 Mn | 67.84 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2024 | 53,000.00 |
| Jun 30, 2024 | 96,000.00 |
| Mar 31, 2024 | 181,000.00 |
| Dec 31, 2023 | 206,000.00 |
| Sep 30, 2023 | 234,000.00 |
| Jun 30, 2023 | 106,000.00 |
| Mar 31, 2023 | 244,000.00 |
| Dec 31, 2022 | 157,000.00 |
| Sep 30, 2022 | 261,000.00 |
| Jun 30, 2022 | 91,000.00 |
| Mar 31, 2022 | 172,000.00 |
| Dec 31, 2021 | 50,000.00 |
| Sep 30, 2021 | 151,000.00 |
| Jun 30, 2021 | 409,000.00 |
| Mar 31, 2021 | 469,000.00 |
| Dec 31, 2020 | 450,000.00 |
| Sep 30, 2020 | 423,000.00 |
| Jun 30, 2020 | 58,000.00 |
| Dec 31, 2019 | 262,000.00 |
API Access
Kalaris Therapeutics Receivables - Accured API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=receivables-accured&ticker=KLRS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "receivables-accured", "ticker": "KLRS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=receivables-accured&ticker=KLRS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();